Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 2, 2006, Pages 864-870

  Lam, Justine L ^a   Shugarts, Sarah B ^a   Okochi, Hideaki ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; DEXAMETHASONE; DIGOXIGENIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1A4; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG UPTAKE; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; AREA UNDER CURVE; DIGOXIN; HEPATOCYTES; LIVER; MALE; ORGANIC ANION TRANSPORT PROTEIN 1; RATS; RATS, WISTAR; RIFAMPIN;

EID: 33751160865     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.108282     Document Type: Article

References (29)

1. Benet LZ and Galeazzi RL (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68:1071-1074.
2. Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, and Brosen K (2004) Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 60:109-114.
3. Christians U, Jacobsen W, Serkova N, Benet LZ, Vidal C, Sewing KF, Manns MP, and Kirchner GI (2000) Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl 748:41-53.
4. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, and Stieger B (2000) Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32:82-86.
5. Guo GL, Choudhuri S, and Klaassen CD (2002) Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers that activate gene expression through ligand-activated transcription factor pathways. J Pharmacol Exp Ther 300:206-212.
6. Harrison LI and Gibaldi M (1976) Pharmacokinetics of Dg3 in the rat. Drug Metab Dispos 4:88-93.
7. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82.
8. Kullak-Ublick GA and Becker MB (2003) Regulation of drug and bile salt transporters in liver and intestine. Drug Metab Rev 35:305-317.
9. Lam JL and Benet LZ (2004) Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of Dg3 metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 32:1311-1316.
10. Lam JL, Okochi H, Huang Y, and Benet LZ (2006) In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos 34:1336-1344.
11. Lau YY, Huang Y, Frassetto L, and Benet LZ (2006a) Effects of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther, in press.
12. Lau YY, Okochi H, Huang Y, and Benet LZ (2006b) Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762-771.
13. Lau YY, Okochi H, Huang Y, and Benet LZ (2006c) Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, intestinal and hepatic metabolism. Drug Metab Dispos 34:1175-1181.
14. Lau YY, Wu CY, Okochi H, and Benet LZ (2004) Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 308:1040-1045.
15. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, and Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Investig 102:1016-1023.
16. Letschert K, Faulstich H, Keller D, and Keppler D (2006) Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 91:140-149.
17. Li C, Benet LZ, and Grillo MP (2002) Enantioselective covalent binding of 2-phenylpropionic acid to protein in vitro in rat hepatocytes. Chem Res Toxicol 15:1480-1487.
18. Li L, Meier PJ, and Ballatori N (2000) Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol Pharmacol 58:335-340.
19. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, and Neuvonen PJ (2005) Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77:468-478.
20. Salphati L and Benet LZ (1998) Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol 55:387-395.
21. Salphati L and Benet LZ (1999) Metabolism of Dg3 and digoxigenin digitoxosides in rat liver microsomes: involvement of cytochrome P4503A. Xenobiotica 29:171-185.
22. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, and Kim RB (2005) Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 33:676-682.
23. Schuetz EG (2001) Induction of cytochromes P450. Curr Drug Metab 2:139-147.
24. Shitara Y, Itoh T, Sato H, Li AP, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616.
25. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, and Sugiyama Y (2002) Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res (NY) 19:147-153.
26. Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, et al. (2004) Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 48:4306-4314.
27. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, and Hori R (1992) Transport of Dg3 by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840-845.
28. Tirona RG, Leake BF, Wolkoff AW, and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228.
29. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, and Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172.